CNPY2 drives DSS-induced colitis via the macrophage-ROS axis

Area of Science:

• Immunology
• Gastroenterology
• Molecular Biology

Background:

• Inflammatory bowel disease (IBD) is a chronic gastrointestinal inflammatory condition with unclear mechanisms.
• Genetic, environmental, and immune factors contribute to IBD pathogenesis.
• Macrophage activity is implicated in IBD progression.

Purpose of the Study:

• To investigate the role of CNPY2 in inflammatory bowel disease (IBD).
• To elucidate the mechanisms by which CNPY2 influences colitis.
• To determine the impact of CNPY2 on macrophage function and reactive oxygen species (ROS) production.

Main Methods:

• Utilized whole-body Cnpy2 knockout (KO) mouse models.
• Induced colitis using dextran sodium sulfate (DSS) in wild-type and Cnpy2 KO mice.
• Analyzed mucosal barrier integrity, macrophage populations (LPMφs), cytokine production, and ROS levels.

Main Results:

• Cnpy2 KO mice exhibited significantly reduced DSS-induced colitis.
• Reduced mucosal barrier disruption and fewer lamina propria macrophages (LPMφs) were observed in Cnpy2 KO mice.
• Diminished proinflammatory cytokine production and lower ROS generation by Cnpy2 KO macrophages were noted, with CHOP regulation implicated.
• N-acetyl-L-cysteine (NAC) treatment abolished colitis in Cnpy2 KO mice, highlighting the role of ROS.

Conclusions:

• CNPY2 exacerbates DSS-induced colitis through macrophage-specific mechanisms.
• ROS upregulation driven by CNPY2 is central to its pathogenic role in colitis.
• Targeting CNPY2 or ROS may offer therapeutic strategies for IBD.